t3d-959
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Jul 1, 2015 (NCT02560753)
Timeline
Indications
Studied for
Mechanism of action
PPARD agonist
Ph1b study completed in 2011 (no trial ID). Compound outlicensed to T3D Therapeutics Inc in 2013.
PPARG agonist
Ph1b study completed in 2011 (no trial ID). Compound outlicensed to T3D Therapeutics Inc in 2013.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545176 ↗
Also known as
- db959
- db-959
- db-959
- t3d-959
- t3d-959
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06964230 | Phase 2/Phase 3 (Phase 3) | Oct 26, 2026 | T3D Therapeutics, Inc. |
| NCT04251182 | Phase 2 | Feb 5, 2020 | National Institute on Aging (NIA), Pharmaceutical Research Associates, Inc. (PRA), T3D Therapeutics, Inc. |
| NCT02560753 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2015 | T3D Therapeutics, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| T3D Therapeutics, Inc. | For profit | 3 | 3 | 2 | 2015 |
| National Institute on Aging (NIA) | Government | 1 | 0 | 1 | 2020 |
| Pharmaceutical Research Associates, Inc. (PRA) | For profit | 1 | 0 | 1 | 2020 |
3 organizations
Page 1 / 1